β-Lactoglobulin tablets as a suitable vehicle for protection and intestinal delivery of probiotic bacteria
Pictures of tablets made of native, 50% succinylated or 100% succinylated β-lg before and 1 after incubation in simulated gastric fluid with pepsin for 30, 60 or 120 min. The use of succinylated β-lactoglobulin as a novel functional tablet excipient for the protection of probiotic bacteria against t...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2011-02, Vol.405 (1), p.47-54 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Pictures of tablets made of native, 50% succinylated or 100% succinylated β-lg before and 1 after incubation in simulated gastric fluid with pepsin for 30, 60 or 120
min.
The use of succinylated β-lactoglobulin as a novel functional tablet excipient for the protection of probiotic bacteria against the adverse gastric conditions and their delivery in the intestine was studied. Tablets were produced by direct compression of a dry mixture of
Bifidobacterium longum HA-135 and the tested excipient. The results showed that tablets made of native β-lg did not ensure cell survival while grafting carboxylic acid groups on the protein revealed to be an innovative method to create a gastroresistant matrix that could allow the survival of up to 10
8
CFU and 10
7
CFU after 1
h and 2
h gastric incubation, respectively. When compared to other polymers, succinylated β-lg promoted the best survival both upon compression and after simulated gastric passage. The proportion of succinylated β-lg in the formulation could be lowered to 60% without modifying the protective ability of the matrix. Additionally, the tablets proved to be stable over a period of 3 months when refrigerated. Succinylated β-lg tablets are an interesting vehicle for the protection of acid-sensitive bacteria during transit in the upper gastro-intestinal tract. |
---|---|
ISSN: | 0378-5173 1873-3476 |
DOI: | 10.1016/j.ijpharm.2010.11.041 |